This article was downloaded by: [UQ Library] On: 28 April 2013, At: 01:11 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

Synthesis and Anti-HIV Activity of 6-Substituted Purine 2'-Deoxy-2'-fluororibosides

Tokumi Maruyama^a, Kunihiko Utzumi^a, Yoshiko Sato^a & Douglas D. Richman^b

^a Department of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima, 770, JAPAN

^b Departments of Pathology and Medicine, University of California, San Diego, La Jolla, California, 92093-0679, U.S.A. Version of record first published: 23 Sep 2006.

To cite this article: Tokumi Maruyama , Kunihiko Utzumi , Yoshiko Sato & Douglas D. Richman (1994): Synthesis and Anti-HIV Activity of 6-Substituted Purine 2'-Deoxy-2'-fluororibosides, Nucleosides and Nucleotides, 13:1-3, 527-537

To link to this article: http://dx.doi.org/10.1080/15257779408013260

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <u>http://www.tandfonline.com/page/terms-and-conditions</u>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND ANTI-HIV ACTIVITY OF 6-SUBSTITUTED PURINE 2'-DEOXY-2'-FLUORORIBOSIDES¹⁾

Tokumi Maruyama^{*},^a Kunihiko Utzumi,^a Yoshiko Sato,^a and Douglas D. Richman^b

^aDepartment of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770, JAPAN, ^bDepartments of Pathology and Medicine, University of California, San Diego, La Jolla, California 92093-0679, U.S.A.

ABSTRACT

3',5'-Di-O-protected 6-chloropurine arabinoside 4b was treated with diethylaminosulfur trifluoride (DAST) and subsequently deprotected with pyridinium *p*-toluenesulfonate to give 6-chloropurine 2'-deoxy-2'-fluororiboside 6a. The displacement with nucleophile afforded the 6-substituted congener 6b-e. Treatment of 5'-O-protected 6-chloropurine arabinoside 3c with DAST gave lyxoepoxide 7.

INTRODUCTION

A series of 2'-deoxy-2'-fluoronucleosides have been prepared.²⁾ One of these, 2'deoxy-2'-fluorocytidine (dCfl), exhibited antiviral activity against herpes simplex virus (HSV).³⁾ Because some 6-substituted purine nucleosides are known to show significant activity in cancer chemotherapy,⁴⁾ we decided to evaluate the biological activity of 6substituted purine 2'-deoxy-2'-fluororibosides. Also reported here are the one step synthesis of lyxo-epoxide from arabinoside.

This paper is dedicated to the late Professor Roland K. Robins who passed away during the summer of 1992.

SYNTHESIS

The syntheses of 2'-deoxy-2'-fluoronucleosides have been accomplished by several routes including nucleophilic displacement of 2'-O-trifluoromethanesulfonylarabino-sides.²⁾ Recently, a method to introduce fluorine into the sugar moiety of nucleosides using DAST has been developed.⁵⁾ We adopted this reagent for the syntheses of 6-substituted purine 2'-deoxy-2'-fluororibosides.

An attempt at the conversion of 1a to 2'-O-acetyl arabinoside 2 has been made by application of the method of Fukukawa et $al.^{6}$ Thus, treatment of 1a with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane afforded the corresponding 3',5'-O-(tetraisopropyldisiloxane-1,3-diyl) derivative 1b. Compound 1b was allowed to react in pyridine with trifluoromethanesulfonyl chloride in the presence of 4-dimethylaminopyridine to give the 2'-O-triflate 1c in high yield. An SN2 displacement with acetate anion at the 2'position of 1c was employed to obtain the 2'(S)(ara)-O-acetate 2. At this stage, the silvl protecting group should be changed to a group which is stable under fluoride anion. Desilylation of 2 with 2 equivalent of tetrabutylammonium fluoride in the presence of acetic acid at 0° for 15 min afforded 3a.⁷) Since acyl protection causes neighboring group participation in the nucleophilic substitution of 3',5'-di-O-acetyl-2'-O- methanesulfonylarabinosides by azido anion, an etheral group has been chosen.^{8a)} Reaction of 3a with 3,4-dihydro-2H-pyran and deacylation by ammonia in methanol gave 3',5'-di-Oprotected arabinoside 4b. Treatment of 4b with DAST in the presence of pyridine in CH₂Cl₂ afforded 5 in 50% yield and recovered 4b in 27% yield. No spot other than 4b and 5 was observed on TLC. When the DAST reaction was tried in the absence of pyridine, the protecting group was partially removed from 4b and 5. Hydrolysis of 5 with pyridinium p-toluenesulfonate (PPTS) in ethanol gave 6-chloro-9-(2-deoxy-2fluoro-B-D-ribofuranosyl)purine 6a, a key intermediate for the synthesis of basemodified analogues. The ¹H-NMR spectrum of **6a** indicated that the 2'-fluorine caused a downfield shift of the 2'-proton and a large H2'-C-F geminal coupling (52.5Hz). Reaction of 6a with liquid ammonia gave the known product 6b, which was identical in all respects to the published data.^{8b)} Therefore, the structure of **6a** was unequivocally determined. Similar reactions of 6a with various nucleophiles afforded 6-substituted congeners 6c-e (Chart 1).

Tritylaion of 3a gave 5'-O-trityl analog 3b and subsequent deacetylation of the product afforded 3c. When 3c was treated with DAST in a similar manner to 4b,





disappearance of the starting material was observed on TLC. Work-up of the reaction mixture gave *lyxo* epoxide 7 in 56% yield. The ¹H-NMR spectrum of the product showed that the signals derived from the sugar protons are close to those of 1-(2,3-anhydro-5-O-trityl- β -D-lyxofuranosyl)thymidine.⁹⁾ The structure of 7 was finally confirmed by an alternative synthesis. Treatment of **3b** with methanesulfonyl chloride gave 3'-O-mesylate **8**. Deacetylation and ring formation occurred on the treatment of **8** with liquid ammonia. The lyxo-epoxide 7 thus obtained was identical in all respects with the former sample. The reaction mechanism could be explained by the initial attachment of diethylaminosulfur difluoride group to the less hindered 3'-OH function followed by the intramolecular attack of 2'-OH (Chart 2).

BIOLOGICAL ACTIVITY

The antiviral activity of 6a-e were assayed by HIV plaque reduction in CD4 expressing HeLa cell monolayers as previously described¹⁰⁾ (Table I). Both 6a and 6b displayed indications of activity against HIV-l in this series. In contrast, 6c-e proved



Chart 2

inactive against HIV-l indicating that the exocyclic amino of adenine are essential for the antiviral effect of 2'-deoxy-2'-fluoro purinenucleosides. Because modified nucleosides may not serve as substrates for cellular nucleoside kinases, further modifications that would lead to phosphate or phosphonate derivatives should be attempted to increase potential anti-HIV activity.

EXPERIMENTAL

Melting points (mp) were determined using a Yanagimoto micro-melting point apparatus (hot stage type) and are uncorrected. UV spectra were recorded with a Shimadzu UV-190 digital spectrometer. Low resolution mass spectra were obtained on a Shimadzu-LKB 9000B mass spectrometer in the direct-inlet mode. High resolution mass spectra were obtained on a JMS AX-500 spectrometer in the direct-inlet mode. ¹H-NMR spectra were recorded on either Varian UNITY 200 (200 MHz) or Varian UNITY 600 (600 MHz) in CDCl₃ (or dimethyl sulfoxide (DMSO)- d_6) with tetramethylsilane as an internal standard. Merck Art 5554 plates precoated with silica gel 60 containing fluorescent indicator F_{254} were used for thin-layer chromatography and silica gel 60 (Merck 7734, 60 - 200 mesh) was employed for column chromatography.

Compound	Concentration(μ M)	Average	% Reduction
6a	10	79	32
	1.0	116	0
	none	116	
6 b	10	78	33
	1.0	120	0
6 c	10	109	6
	1.0	119	0
6 d	10	110	5

Table 1. Inhibition of HIV-1 plaque formation by compounds 6a-d

The assay was performed by inhibition of plaque formation in CD4 expressing HeLa cells using the HIV- 1_{LA1} (LAV-1) virus



6 series a ; X=Cl, b ; X=NH₂ c ; X=NMe₂, d ; X=SH 532

6-Chloro-9-(3,5-*O*-tetraisopropyldisiloxane-1,3-diyl-β-D-ribofuranosyl)purine (1b). 6-Chloropurine riboside 1a (37.21 g, 0.13 mol) and imidazole (40.0 g, 1.1 eq.)were dissolved in DMF (130 ml), and 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (46.0 ml, 1.1 eq.) was added to the solution and the mixture was stirred at room temperature for 1 h. The residue obtained after work-up of the solution was chromatographed over a column of silica gel G (5.0 × 29 cm) with CHCl₃ (3.7 l) and the residue thus obtained was crystallized from MeOH to give white crystals (47.52 g, 69%). Anal.cald. for $C_{22}H_{37}ClN_4O_5Si_2: C,49.94$; H,7.05; N,10.59. Found C,49.82; H,7.14; N,10.83. Ms m/z 485, 487 (M⁺-C₃H₇) mp.106-108°C UV: λ max 264.5nm, 250nm (sh) (MeOH), 264nm, 250nm (sh) (0.05N HCl) ¹H-NMR (CDCl₃) δ : 8.69 (1H, s, H8), 8.28 (1H, s, H2), 6.05 (1H, s, H1'), 5.02 (1H, t, H2', *J*=5.60Hz), 4.57 (1H, d, H3', *J*=5.60Hz), 3.99-4.18 (3H, m, H4' and H5'), 3.14 (1H, d, 2'-O<u>H</u>), 1.1 (28H, -C<u>H</u>(C<u>H₃)₂×4).</u>

6- Chloro-9-(3,5-O-tetraisopropyldisiloxane-1,3-diyl-2-O-triflyl-β-D-ribofuranosyl)purine (1c). Compound 1b (14.3 g, 27.0 mmol) and 4-dimethylaminopyridine (5.40 g) were dissolved in a mixture of triethylamine (6.7 ml) and CH₂Cl₂ (270 ml), then ice-cooled. Trifluoromethanesulfonyl chloride (5.4 ml) was added to the solution and the mixture was stirred at room temperature for 30 min. The usual workup of the resulting solution and crystallization from MeOH gave white crystals (12.3 g, 69%). Anal.cald. for C₂₃H₃₆F₃Cl N₄O₇SSi ₂: C,41.78 ; H,5.49 ; N,8.47. Found C,41.79 ; H,5.41 ; N,8.14. mp.101-102°C UV: λ max 264nm, 250nm (sh) (MeOH), 263.5nm, 250nm (sh) (0.05N HCl) ¹H-NMR (CDCl₃) δ : 8.71 (1H, s, H8), 8.34 (1H, s, H2), 6.23 (1H, s, H1'), 5.67 (1H, d, H2', J=4.72Hz), 5.09 (1H, dd, H3', J=9.17Hz, J=4.72Hz), 4.00-4.26 (3H, m, H4', H5'), 1.1 (28H, -CH(CH₃)₂×4).

6-Chloro-9-(2-O-acetyl-3,5-O-tetraisopropyldisiloxane-1,3-diyl-β-D-arabinofuranosyl)purine (2). A solution of 1c (20.04 g, 30.3 mmol) and NaOAc (12.4 g, 5 eq.) in DMF (10 ml) was stirred at room temperature overnight and filtered to remove insoluble materials. The usual workup of the filtrate and crystallization from MeOH gave white crystals (12.3 g, 78%). Anal.cald. for $C_{24}H_{39}ClN_4O_6Si_2$: C,50.47 ; H,6.88 ; N,9.81. Found C,50.62 ; H,7.25 ; N,9.89. Ms m/z 527, 529 (M⁺-C₃H₇) mp.141-143 °C UV: λ max 264nm, 250nm (sh) (MeOH), 264nm, 250nm (sh) (0.05N HC1) ¹H-NMR (CDCl₃) δ : 8.72 (1H, s, H8), 8.35 (1H, s, H2), 6.52 (1H, d, H1', *J*=6.55Hz), 5.59 (1H, dd, H2', J=8.46Hz, J=6.55Hz), 4.90 (1H, t, H3', J=8.46Hz), 4.14 (2H, m, H5'), 3.97 (1H, m, H4'), 1.69 (3H, s, 2'-OCOCH₃), 1.1 (28H, -CH(CH₃)₂×4).

6-Chloro-9-(2-O-acetyl-β-D-arabinofuranosyl)purine (3a). To an ice-cooled solution of 2 (1.14 g, 2.0 mmol) in THF (10 ml) and acetic acid (0.23 ml) was added dropwise 1.0 M tetrabutylammonium fluoride solution in THF (4 ml, 4 eq.) and stirred at 0° for 10 min. The solution was concentrated to a small volume and subjected to a column of silica gel G (2.8 × 15 cm) using a 0 - 10% EtOH in CHCl₃ (1 l) as an eluent. The fraction was collected and the solution was evaporated to give a syrup, which was crystallized from EtOH to afford white crystals (395 mg, 60%). Anal.cald. for $C_{12}H_{13}CIN_4O_5$: C,43.84 ; H,3.96 ; N,17.05. Found C,43.86 ; H,4.00 ; N,16.94. mp. 179-180°C UV: λ max 264nm, 250nm (sh) (MeOH), 264nm, 250nm (sh) (0.05N HCl) ¹H-NMR (DMSO-d₆) δ : 8.89 (1H, s, H8), 8.81 (1H, s, H2), 6.59 (1H, d, H1', J=5.86Hz), 5.90 (1H, d, 3'-OH, J=5.86Hz), 5.38 (1H, t, H2', J=5.86Hz), 5.14 (1H, t, 5'-OH, J=5.50Hz), 4.45 (1H, q, H3', J=5.86Hz), 3.93 (1H, m, H4'), 3.74 (2H, m, H5'), 1.68 (3H, s, 2'-OCOCH₃)

6-Chloro-9-(2-O-acetyl-3,5-di-O-(tetrahydro-2-pyranyl)- β -D-arabinofuranosyl)purine (4a). To a solution of 3a (2.58 g, 7.85 mmol) in DMF (14 ml) and 3,4-dihydro-2H-pyran (6.8 ml) was added p-toluenesulfonic acid (2.74 g) and the solution was stirred at room temperature for 2 h. After neutralization with triethylamine (2 ml), the solution was subjected to the usual workup and silica gel chromatography to give a caramel (3.9 g, quantitative). UV: λ max 264nm, 250nm (sh) (MeOH).

6-Chloro-9-(3,5-di-O-(tetrahydro-2-pyranyl)-β-D-arabinofuranosyl)purine (4b). The acetate 4a (3.92 g, 7.89 mmol) was dissolved in methanol (20 ml) saturated with ammonia and kept at 0° for 3 h. Evaporation of the solution afforded a caramel (3.42 g, 95%). Ms m/z 454, 456 (M^+) UV: λ max 264nm, 250nm (sh) (MeOH).

6-Chloro-9-(2-deoxy-2-fluoro-3,5-di-O-(tetrahydro-2-pyranyl)- β -D-ribofuranosyl)purine (5). To a cooled solution (- 60°) of 4b (1.42 g, 3.12 mmol) in a mixture of CH₂Cl₂ (25 ml) and pyridine (3.2 ml) was added DAST (1.67 ml, 4 eq.) dropwise under N₂ atmosphere. Teflon equipments were used for flask and pipette. After 6 h at room temperature, the solution was poured into the stirred solution of 10% NaHCO₃ (50 ml) and diluted with CH₂Cl₂ (25 ml). The organic layer was washed with water (50 ml × 3), dried over MgSO₄ and evaporated to a small volume. The solution was chromatographed over a column of silica gel G (2.5 × 26 cm) with 0 - 68% AcOEt in hexane (2 *l*). From the first fraction **5** was obtained as a caramel (716 mg, 50%). UV: λ max 264nm, 250nm (sh) (MeOH). Starting material **4b** was recovered from the second fraction as a caramel (27%).

6-Chloro-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)purine (6a). A solution of 5 (716 mg, 1.57 mmol) in EtOH (30 ml) was stirred in the presence of pyridinium *p*-toluenesulfonate at 50° for 8 h and the solution was concentrated to 3 ml. The solution was chromatographed over a column of silica gel G (2.0 × 43 cm) with 0 - 12.5% AcOEt in CHCl₃ (2 l) to give white crystals (307 mg, 68%). Anal.cald. for $C_{10}H_{10}CIN_4O_3$: C,41.61 ; H,3.49 ; N,19.41. Found C,41.70 ; H,3.68 ; N,18.98. Ms m/ z 288, 290 (M⁺) mp. 209-212°C UV: max 264nm, 250nm (sh) (H₂O), 264nm, 250nm (sh) (0.05N HCl) ¹H-NMR (DMSO-d₆) δ : 8.92 (1H, s, H8), 8.83 (1H, s, H2), 6.39 (1H, dd, H1', J_{H1'- F}=16.85Hz, J_{H1'- H2}=1.83Hz), 5.78 (1H, d, 3'-OH, J=6.23Hz), 5.46 (1H, ddd, H2', J_{H2'- F}=52.75Hz, J_{H2'- H3}=4.3Hz, J_{H1'- H2}=1.83Hz), 5.18 (1H, br s, 5'-OH), 4.51 (1H, m, H3', J_{H3'- F}=22.34Hz), 4.02 (1H, m, H4'), 3.81, 3.63 (each 1H, m, H5').

2'-Deoxy-2'-fluoroadenosine (6b). Compound **6a** (100 mg, 0.35 mmol) was reacted with liquid ammonia (1 ml) in 10 ml of steel-bomb at 40° overnight. Ammonia was carefully evaporated and the solid was crystallized from MeOH to give white crystals (71 mg, 74%). Anal. cald. for $C_{10}H_{12}FN_5O_3$: C,44.61 ; H,4.49 ; N,26.01. Found C,44.25 ; H,4.54 ; N,25.77. Ms m/z 269 (M⁺) mp. 209-212°C UV: λ max 259nm (H₂O), 255.5nm (0.05N HCl), 259nm (0.05N NaOH) ¹H-NMR (DMSO-d₆) δ : 8.37 (1H, s, H8), 8.16 (1H, s, H2), 7.36 (2H, br s, 6-NH₂), 6.23 (1H, dd, H1', J_{H1'-F}=16.85Hz, J_{H1'-H2'}=2.93Hz), 5.72 (1H, d, 3'-OH, J=5.86Hz), 5.44 (1H, ddd, H2', J_{H2'-F}=52.76Hz, J_{H2'-H3'}=4.4Hz, J_{H1'-H2'}=2.93Hz), 5.28 (1H, t, 5'-OH, J=5.13Hz), 4.49 (1H, m, H3', J_{H3'-F}=17.71Hz), 3.99 (1H, m, H4'), 3.75, 3.59 (each 1H, m, H5').

2'-Deoxy-2'-fluoro- N^6 , N^6 -dimethyladenosine (6c). 50% Dimethylamine (0.20 ml, 6 eq.) was added to a solution of **6a** (100 mg, 0.35 mmol) in DMF (4 ml) and the solution was stirred at at room temperature for 2 h. After evaporation of the solution, the residue was chromatographed over a column of silica gel G (2.0 × 20 cm) with 0 - 5% EtOH in CHCl₃ (1.3 l) to give white crystals (72 mg, 69%). Anal. cald. for $C_{12}H_{16}FN_5O_3$: C,48.48; H,5.42; N,23.56. Found C,48.19; H,5.50; N,23.03. Ms m/z 297 (M⁺) mp. 113-115°C UV: λ max 273nm (MeOH), 267.5nm (0.05N HCl), 275nm

(0.05N NaOH) ¹H-NMR (DMSO- d_6) δ : 8.38 (1H, s, H8), 8.22 (1H, s, H2), 6.24 (1H, dd, H1', $J_{H1'-F}$ =16.8Hz, J=2.31Hz), 5.70 (1H, d, 3'-OH, J=6.92Hz), 5.42 (1H, m, H2', $J_{H2'-F}$ =52.5Hz), 5.24 (1H, m, 5'-OH), 4.46 (1H, m, H3', $J_{H3'-F}$ =22.5Hz), 3.98 (1H, m, H4'), 3.68(2H, m, H5'), 3.45(6H, br s, 6-N(CH₂)₂).

6-Mercap to-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)purine (6d). Hydrogen sulfide was introduced to a suspension of NaH (42 mg, 3 eq.) in DMF (5 ml) at 0 ° for 10 min and N₂ was passed into the solution to disperse the excess gas. 6-Chloro compound 6a (100 mg, 0.35 mmol) was added to the solution and the mixture was stirred at room temperature for 1 h, then neutralized with acetic acid (0.06 ml). After bubbling N₂ gas for 30 min, the solution was evaporated to dryness and the residue was crystallized from EtOH to give white crystals (75 mg, 74%). Ms m/z 286 (M⁺). mp. 270 °C(dec.) UV: λ max 320nm, 224nm (H₂O), 322nm, 224nm (0.05N HCl), 311nm, 232nm (0.05N NaOH). ¹H-NMR (DMSO-d₆) δ : 8.31 (1H, s, H8), 8.13 (1H, s, H2), 6.18 (1H, dd, H1', J_{H1'-F}=16.6Hz, J=2.31Hz), 5.37 (1H, ddd, H2', J_{H2'-F}=52.8Hz, J=4.06Hz, J=2.31Hz), 4.44 (1H, m, H3', J_{H3'-F}=21.1Hz), 3.98 (1H, m, H4'), 3.66(2H, m, H5').

6-Methylmercapto-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)purine (6e). To a solution of 6a (100 mg, 0.35 mmol) in anhydrous EtOH (5 ml) was added sodium thiomethoxide (15% solution in water, 0.46 ml, 3 eq.) and the solution was stirred at room temperature for 30 min. After evaporation of the solution, the residue was chromatographed over a column of silica gel G (2.3 × 15 cm) with 0 - 5% EtOH in CHCl₃ (1.1 l) to give a caramel (77 mg, 74%). Ms m/z 297 (M⁺). UV: λ max 283nm, 289nm(sh) (MeOH), 289nm, 284nm(sh) (0.05N HCl), 284nm, 289nm(sh) (0.05N NaOH). ¹H-NMR (DMSO-d₆) δ : 8.75 (1H, s, H8), 8.63 (1H, s, H2), 6.33 (1H, dd, H1', J_{H1'-F}=17.0Hz, J=2.4Hz), 5.73 (1H, d, 3'-OH, J=6.4Hz), 5.45 (1H, ddd, H2', J_{H2-F}=52.8Hz, J=4.6Hz, J=2.4Hz), 5.13 (1H, m, 5'-OH), 4.49 (1H, m, H3', J_{H3'-F}=22.5Hz), 3.99 (1H, m, H4'), 3.67(2H, m, H5'), 2.66(3H, s, 6-SCH₁).

6-Chloro-9-(2-O-a cety l-5-O-trityl-β-D-arabinofuranosyl)purine (3b). A solution of 3a (265 mg, 0.81 mmol) and trityl chloride (450 mg, 2 eq.) in pyridine (10 ml) was kept at room temperature overnight. The usual workup of the resulting solution gave a caramel (277 mg, 61%). UV: λ max 263 nm (MeOH), 262nm (0.05N HCl) ¹H-NMR (CDCl₃) δ : 8.69 (1H, s, H8), 8.26 (1H, s, H2), 7.28-7.47 (15H, m, 5'-OC(C₆H₅)₃), 6.64 (1H, d, H1', *J*=5.9Hz), 5.27 (1H, t, H2', *J*=5.9Hz), 4.60 (1H, m, H3'), 4.19 (1H, q, H4', *J*=5.43Hz), 3.55 (2H, d, H5'), 1.76 (3H, s, 2'-OCOCH₂).

6- Chloro-9-(5-O-trityl-β-D-arabinofuranosyl)purine (3c). The acetate 3b (200 mg, 0.35 mmol) was dissolved in methanol (50 ml) saturated with ammonia and kept at 0° for 3 h. Evaporation of the solution afforded a caramel (180 mg, 97%). UV: λ max 264nm (MeOH), 264nm (0.05N HCl) ¹H-NMR (CDCl₃) δ : 8.68 (1H, s, H8), 8.49 (1H, s, H2), 7.24-7.44 (15H, m, 5'-OC(C₆H₅)₃), 6.45 (1H, s, H1'), 4.38 (1H, s, 3'-OH), 4.32 (2H, s, H2' and H3'), 4.15 (1H, m, H4'), 3.70, 3.47 (each 1H, m, H5').

6-Chloro-9-(2-O-acetyl-3-O-mesyl-5-O-trityl-β-D-arabinofuranosyl)purine (8). Methanesulfonyl chloride (0.04 ml) was added to the solution of 3b (135 mg, 0.24 mmol) in pyridine (5 ml) and the solution was stirred at room temperature for 3 h. The usual workup of the resulting solution gave a caramel (125 mg, 79%). UV: λ max 263nm, 250nm(sh) (MeOH), 263nm (0.05N HCl) ¹H-NMR (CDCl₃) δ : 8.50 (1H, s, H8), 8.23 (1H, s, H2), 7.24-8.49 (15H, m, 5'-OC(C₆H₅)₃), 6.60 (1H, d, H1', *J*=4.76Hz), 5.55(1H, dd, H3', *J*=4.64Hz, *J*=2.84Hz), 5.43(1H, dd, H2', *J*=4.76Hz, *J*=2.84Hz), 4.38 (1H, q, H4', *J*=4.64Hz), 3.56 (2H, d, H5', *J*=4.64Hz), 3.18 (3H, s, 3'-OSO₂CH₃), 1.89 (3H, s, 2'-OCOCH₃).

6-Chloro-9-(2,3-anhydro-5-O-trityl-β-D-lyxofuranosyl)purine (7).

Method 1. To a cooled solution (- 60°) of 3c (321 mg, 0.61 mmol) in a mixture of CH_2Cl_2 (5 ml) and pyridine (1.3 ml) was added DAST (0.66 ml, 8 eq.) dropwise under N₂ atmosphere. After standing at room temperature for 2 h, the solution was treated in a similar manner described in a section of 5 to afford as white crystals (176 mg, 56%). Anal. cald. for $C_{29}H_{23}ClN_4O_3$: C,68.17; H,4.54; N,10.96. Found C,68.03 ; H,4.60; N,11.02. Ms m/z 510, 512 (M⁺) mp.177-179 °C UV: λ max 264nm, 250nm(sh) (MeOH), 264nm (0.05N HCl) ¹H-NMR (CDCl₃) δ : 8.74 (1H, s, H8), 8.40 (1H, s, H2), 7.21-7.45 (15H, m, 5'-OC($C_{6}H_5$)₃), 6.44 (1H, s, H1'), 4.30 (1H, t, H4', J=4.83Hz), 4.07 and 4.06 (1H, s, H2' and 1H, s, H3'), 3.46 (2H, m, H5').

Method 2. 3'-O-Mesylate 8 (150 mg) was reacted with liquid ammonia (1 ml) in 10 ml of steel-bomb at 0° for 30 min. Ammonia was carefully evaporated and the solid was crystallized from MeOH to give white crystals (83.5 mg, 70%). The product thus obtained was identical in any respect with sample obtained by method 1.

ACKNOWLEDGEMENTS

Tokumi Maruyama was supported by a grant-in-Aid for Scientific Research on Priority Areas, No. 04226218, from the Ministry of Education, Science and Culture, Japan. Douglas D. Richman was supported by AI-27670, AI-30457, and AI-29164 from the U. S. National Institutes of Health and by the Research Center for AIDS and HIV Infection of the San Diego Veterans Affairs Medicinal Center.

REFERENCES AND NOTES

- a) Part of this work was presented at the 19th Symposium on Nucleic Acids Chemistry, Fukuoka, November 1992 [Nucleic Acids Symposium Series, No. 27, p.79 (1992)]. b) Recently enzymatic synthesis and anti-influenza virus activity of purine 2'-deoxy-2'-fluororibosides has been reported by Welcome Research Laboratories. J. V. Tuttle, M. Tisdale, and T. A. Krenitsky, J. Med. Chem., 36, 119 (1993).
- a) M. Ikehara, T. Maruyama, and H. Miki, *Tetrahedron*, 34, 1133 (1978).
 b) M. Ikehara, *Heterocycles*, 21, 75 (1984) and the references cited therein.
- F. Wohlrab, A. T. Jamieson, J. Hay, R. Mengel, and W. Guschlbauer, *Biochim. Biophs. Acta*, 824, 233 (1985).
- 4. A. Goldin, H. B. Wood, Jr., and R. R. Engle, *Cancer Chemother., Rep.* Part 2, 1, 1 (1968).
- D. B. Olsen, H. A. Benseler, W. A. Pieken, and F. Eckstein, *Biochemistry*, 30, 9735 (1991).
- K. Fukukawa, T. Ueda, and T. Hirano, *Chem. Pharm. Bull.*, **31**, 1582 (1983) and Y. Sato, T. Maruyama, and M. Honjo, *ibid.*, **37**, 1604 (1989).
- D. C. Baker, S. D. Kumar, W. J. Waites, G. Arnett, W. M. Shannon, W. I. Higuchi, and W. J. Lambert, J. Med. Chem., 27, 270 (1984).
- a) M. Ikehara and T. Maruyama, *Tetrahedron*, **31**,1369 (1975).
 b) M. Ikehara and H. Miki, *Chem. Pharm. Bull.*, **26**, 2449 (1978).
- J. -T. Huang, L. -C. Chen, L. Wang, M. -H. Kim, J. A. Warshaw, D. Armstrong, Q. -Y. Zhu, T. -C. Chou, K. A. Watanabe, J. Matulic-Adamic, T. -L. Su, J. J. Fox, B. Polsky, P. A. Baron, F. W. M. Gold, W. D. Hardy, and E. Zuckerman, J. Med. Chem., 34, 1640 (1991).
- B.A. Larder, B. Chesebro, and D. D. Richman, Antimicrob. Agents & Chemother., 34, 436 (1990).

Received 7/14/93 Accepted 10/18/93